Drug Discovery World

JUNE 22, 2023

This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralising antibodies. “We The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

Pharmaceutical Technology

MARCH 1, 2023

Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Drug Discovery World

DECEMBER 21, 2023

Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker.

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

Pharmaceutical Technology

MARCH 9, 2023

In-vitro T-cell activation is a key innovation area in immuno-oncology T cells can be activated and differentiated in vitro by crosslinking the TCR with CD3 antibodies and PMA treatment. Activation of T-cell proliferation specifically in a tumour is crucial for reducing the autoimmune side effects of antitumour immunotherapy.

In-Vitro 130

In-Vitro Gene Editing Medicine Licensing 130

Drug Discovery World

NOVEMBER 27, 2023

As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies to treat various disorders such as rheumatologic diseases, cancer, diabetes, anaemia, and infectious diseases becomes paramount. References Mistry RK, Kelsall E, Sou SN, et al.

Production 59

Production Engineer Gene Editing Gene 59

Drug Discovery World

MARCH 10, 2023

Company launches ADC Phase I trial in solid tumours Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2.

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials Drugs 52

Pharmaceutical Technology

JANUARY 19, 2023

However, it is possible to target CD33 in the clinic, as evidenced by the FDA approval of Pfizer’s anti-CD33 antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) in 2000. The first clinical attempt at managing AML with CAR-T cells was reported in 2013 with a small Phase I study that did not demonstrate activity.

Marketing 130

Marketing Gene Editing Production Sales 130

Drug Discovery World

FEBRUARY 28, 2024

Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. A Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether a type of antibody called IgE could be used to treat cancer.

Development 65

Development Research Drugs Antibody 65

pharmaphorum

AUGUST 8, 2022

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing.

Marketing 111

Marketing Sales Gene Editing Antibody 111

Drug Discovery World

JULY 3, 2023

Dr Agapitos Patakas, CSO, Research & Development, Antibody Analytics, presented in this track on a customisable cell line platform for in vitro assessment of safety and efficacy of immune cell-directed therapies. The post Immuno-Oncology Summit Europe 2023: Programme highlights appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

XTalks

OCTOBER 12, 2021

They found that removal of the protein using gene editing technology led to severe early onset arthritis as well as bone loss in two rat models. antibodies in the knockout (KO) rats. In rescue experiments, supplementation of the antibodies through passive immunization did not suppress arthritis. KO animals.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

pharmaphorum

JULY 13, 2021

The Danish drugmaker is paying $100 million upfront for rights to antibody drug PRX004, which is heading for phase 2 trials in cardiomyopathy associated with ATTR amyloidosis, a life-threatening disease affecting the heart and nervous system. The post Novo Nordisk bulks up in rare diseases with $1.2bn Prothena deal appeared first on.

Gene Silencing 98

Gene Silencing Sales Gene Editing Clinical Trials 98

XTalks

MARCH 28, 2024

Furthermore, the introduction of multi-targeted kinase inhibitors and monoclonal antibodies is also being examined as a possible form of therapy. Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

Drug Discovery World

JULY 10, 2023

Artificial intelligence (AI), gene editing, synthetic biology and more, are beginning to prove their usefulness in drug design and development, taking therapies away from the one-size-fits-all approach, towards more definable targets that operate more effectively.

Gene Therapy 52

Gene Therapy Gene Scientist Gene Editing 52

Drug Discovery World

JANUARY 9, 2024

2024 is anticipated to be a transformational year for the pharma industry, with new modalities like antibody drug conjugates and AI/machine learning providing therapies for patients with limited treatment options.

Drugs 69

Drugs Antibody Gene Editing Medicine 69

Drug Discovery World

APRIL 15, 2023

BDC-3042 is an agonistic antibody targeting Dectin-2, an immune-activating receptor expressed by TAMs. In preclinical studies, Surface Oncology has shown that SRF114 induces antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) pathways to deplete intratumoural Treg cells.

Antibody 52

Antibody Trials Research Gene Editing 52

pharmaphorum

FEBRUARY 17, 2022

The pushback has also affected another new drug for SCD, Novartis’ antibody Adakveo (crizanlizumab), used to treat the painful vaso-occlusive crises (VOCs) that periodically afflict people with the disease, which has also been highlighted as a potential blockbuster.

Drugs 59

Drugs Gene Therapy Gene Editing Gene 59

Delveinsight

AUGUST 27, 2020

As observed in 45 younger adults, the middle dose of the vaccine triggered the production of neutralizing antibodies against SARS-CoV-2, the virus, which causes COVID-19 , in 10 patients aged 56 to 70 and 10 patients over 71. Freenome secures USD 270 Million to boost its colorectal cancer blood test.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

JANUARY 24, 2021

. “We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND,” said David Main , President and Chief Executive Officer of Notch.

Engineer 52

Engineer Gene Editing Genome Genomics 52

XTalks

NOVEMBER 30, 2023

These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. In 2021, the FDA granted approval to San Francisco-based Excision BioTherapeutics to start trials assessing CRISPR gene editing as a potential treatment for HIV. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Cloudbyz

MARCH 6, 2024

For example, monoclonal antibodies, a type of biologic, can selectively bind to specific targets such as proteins or cells involved in disease processes, thereby modulating immune responses or inhibiting disease progression. One of the key features of biologics is their ability to mimic or augment natural biological processes within the body.

Gene 72

Gene Immune Response Manufacturing Gene Therapy 72

pharmaphorum

JULY 1, 2021

Synthetic biology has grown exponentially in less than a decade, with CRISPR gene-editing as the key technology driving this through its use in areas like cancer, infectious diseases, and rare, undertreated indications. Here are my key takeaways from SynBioBeta’s conference.

Gene Editing 78

Gene Editing Engineer Development Gene 78

Delveinsight

MARCH 2, 2021

Toripalimab is the first domestic anti-PD-1 monoclonal antibody that received approval for marketing in China. As per the company, its manufacturing platform supports large-scale production and cryopreservation of off-the-shelf, allogeneic NK cell therapies and proprietary CAR-NK and NK-specific gene-editing technologies.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 76

Drugs Life Science Gene Therapy Genome 76

The Pharma Data

NOVEMBER 3, 2020

LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. Data presented have shown that the capsids deliver highly efficient functional transduction of human hepatocytes with improved manufacturability with low levels of pre-existing neutralizing antibodies in human samples.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

pharmaphorum

JULY 13, 2022

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment. dosing of *first patient* with VERVE-101, an in vivo CRISPR base editing medicine. Today: we are announcing.

Gene Editing 98

Gene Editing Trials Drugs Gene 98

Drug Discovery World

NOVEMBER 16, 2022

And from the perspective of Covid-19, O’Connor says that the scientific community’s interest in things such as antibody discovery, gene editing, and synthetic biology, played a role in helping shape the direction of the OIC.

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

MARCH 8, 2024

She speaks with Megan Thomas about the future for Janssen’s investigational medicine nipocalimab and antibody therapeutics at large. Adele Hannigan, Antibody Analytics Dr Adele Hannigan is Chief Business Officer of Antibody Analytics. Read the interview. Read the interview. Read the interview.

Drugs 69

Drugs Gene Editing Contract Manufacturing Antibody 69

Drug Discovery World

NOVEMBER 30, 2023

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. It was presented by Lei Shi, PhD, Senior Vice President, R&D, Biointron Biological, titled: ‘Accelerating early discovery through HTP and high-speed antibody production’.

Antibody 59

Antibody Protein Engineer In-Vivo 59

The Pharma Data

DECEMBER 11, 2020

of Children’s Hospital at TriStar Centennial in Nashville, Tennessee, and colleagues found that gene editing using CRISPR-Cas9 is safe and feasible and can provide clinical benefit to patients with sickle cell disease and transfusion-dependent ß-thalassemia. ASH: CRISPR-Cas9 Gene Editing Promising in TDT, SCD.

Gene Editing 52

Gene Editing Gene Gene Therapy In-Vivo 52

XTalks

JANUARY 4, 2024

The adeno-associated viral (AAV) vector-based gene therapy received approval in Canada for the treatment of adults aged 18 years or older with moderately-severe to severe hemophilia B who are negative for neutralizing antibodies to variant AAV serotype Rh74, Pfizer Canada revealed in its announcement of the approval.

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. for its cGMP-compliant CHOSOURCE platform. in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

The Pharma Data

DECEMBER 27, 2020

Notably, we never modify the DNA of these cells, which avoids some of the safety concerns that have been reported with certain gene-editing technologies. From these cells we apply proprietary methods to manufacture pure populations of only the cell types which we wish to use in patients.

Manufacturing 52

Manufacturing Production Development Clinical Trials 52

Drug Discovery World

JULY 18, 2023

While type II (Cas9) is mainly used for gene-editing applications, CRISPR detecting tools primarily rely on type V (Cas12) and type VI (Cas13) collateral activity. Another promising approach consists of conjugating antibodies, such as an anti-CD38, to the LNPs for targeted delivery into specific tissues.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

SEPTEMBER 28, 2022

The researchers used an antibody (biological molecule), a small molecule (synthetic), and employed CRISPR technology, a gene-editing technique, to successfully delay the spread of metastases by 60-80%. .

Research 52

Research Gene Editing Genetic Engineering Protein 52